Seom clinical guidelines in early stage breast cancer (2018)

HIGHLIGHTS

• who: F. Ayala de la Peu00f1a from the Division of Medical Oncology, Hospital Clu00ednico Lozano Blesa, Zaragoza, Spain Department of Medical Oncology, University Hospital, have published the research work: SEOM clinical guidelines in early stage breast cancer (2018), in the Journal: (JOURNAL)

SUMMARY

The study has to include the evaluation of the estrogen and progesterone receptor and HER2 gene_expression. In node-negative stage I tumors, an alternative less intense regimen with single-agent paclitaxel and trastuzumab for 12 weeks followed by single-agent trastuzumab (to complete a year) may be considered Adjuvant dual . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.